CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
SM Albelda - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
T Yan, L Zhu, J Chen - Experimental Hematology & Oncology, 2023 - Springer
The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
Tumor–antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma
X Ma, L Kuang, Y Yin, L Tang, Y Zhang, Q Fan… - ACS …, 2023 - ACS Publications
Immunotherapy has had a profound positive effect on certain types of cancer but has not
improved the outcomes of glioma because of the blood–brain barrier (BBB) and …
improved the outcomes of glioma because of the blood–brain barrier (BBB) and …
The future of engineered immune cell therapies
Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …
“living drug” when transferred into patients. Therapies based on engineered immune cells …
Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating
M Hamieh, J Mansilla-Soto, I Rivière, M Sadelain - Cancer Discovery, 2023 - AACR
The success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
propelled the field of synthetic immunology and raised hopes to treat solid tumors in a …
Challenges and new technologies in adoptive cell therapy
P Zhang, G Zhang, X Wan - Journal of Hematology & Oncology, 2023 - Springer
Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and …
Advancing CAR T cell therapy through the use of multidimensional omics data
Despite the notable success of chimeric antigen receptor (CAR) T cell therapies in the
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
treatment of certain haematological malignancies, challenges remain in optimizing CAR …
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
Immunotherapy with anti-GD2 antibodies has advanced the treatment of children with high-
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
risk neuroblastoma, but nearly half of patients relapse, and little is known about mechanisms …
Cooperative CAR targeting to selectively eliminate AML and minimize escape
S Haubner, J Mansilla-Soto, S Nataraj, F Kogel… - Cancer cell, 2023 - cell.com
Acute myeloid leukemia (AML) poses a singular challenge for chimeric antigen receptor
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
(CAR) therapy owing to its phenotypic heterogeneity and similarity to normal hematopoietic …
Exploring treatment options in cancer: tumor treatment strategies
Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …
burdened cancer patients with onerous physical and psychological challenges …